SCHEMBL1119743

SCHEMBL1119743

Cn1c(=O)ccc2ccc(CBr)cc21

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 10/20 0.52
BRD4 O60885 3/20 0.52
BRD9 Q9H8M2 3/20 0.52
CA12 O43570 1/20 0.52
CA9 Q16790 1/20 0.52
KAT2B Q92831 1/20 0.52
ALOX5 P09917 5/20 0.40
BACE1 P56817 2/20 0.36
KCNA5 P22460 1/20 0.36
BRD1 O95696 3/20 0.35
BRPF3 Q9ULD4 2/20 0.35
KCNH2 Q12809 1/20 0.35
MCHR2 Q969V1 1/20 0.35
MCHR1 Q99705 1/20 0.35
CYP2D6 P10635 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4408021 0.88 BRPF1 (0.57) BRPF1BRD4BRD9CA12CA9
SCHEMBL763376 0.84 BRPF1 (0.53) BRPF1BRD4BRD9CA12CA9
SCHEMBL30538035 0.76 BRPF1 (0.57) BRPF1BRD4BRD9CA12CA9
SCHEMBL16932310 0.76 BRPF1 (0.57) BRPF1BRD4BRD9CA12CA9
SCHEMBL9388512 0.74 POLB (0.53) BRPF1BRD4
SCHEMBL1119967 0.73 BRPF1 (0.45) BRPF1BRD4BRD9CA12CA9
SCHEMBL1119899 0.73 BRPF1 (0.59) BRPF1BRD4BRD9CA12CA9
SCHEMBL17979340 0.72 BRPF1 (0.37) BRPF1ALOX5KCNA5
SCHEMBL1948671 0.72 BRPF1 (0.57) BRPF1BRD4BRD9CA12CA9
SCHEMBL31743117 0.72 BRPF1 (0.57) BRPF1BRD4BRD9CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569282-B2 Carboxamide compounds and their use CYTOPATHFINDER, INC. (JP) 2013-10-29 US disclosed
US-8569282-B2 Carboxamide compounds and their use CYTOPATHFINDER, INC. (JP) 2013-10-29 US disclosed
US-8569282-B2 Carboxamide compounds and their use CYTOPATHFINDER, INC. (JP) 2013-10-29 US disclosed
EP-2280766-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS CytoPathfinder, Inc. (JP) 2011-02-09 EP disclosed
US-20100331298-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-30 US disclosed
US-20100331298-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-30 US disclosed
US-20100331298-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-30 US disclosed
US-20100324035-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-23 US disclosed
US-20100324035-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-23 US disclosed
US-20100324035-A1 Carboxamide Compounds and Their Use CYTOPATHFINDER, INC. (JP) 2010-12-23 US disclosed
US-5401751-A Enzyme inhibitors for 5-lipoxygenase ZENECA LIMITED (GB) 1995-03-28 US disclosed
US-5350754-A Heterocyclic cycloalkanes ZENECA LIMITED (GB) 1994-09-27 US disclosed
US-5302603-A Lipoxygenase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-04-12 US disclosed
US-5236919-A Inhibitorsof enzyme 5-lipoxygenase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-17 US disclosed
US-5217977-A Lipoxygenase inhibitor for treating diseases medicated by leukotrienes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-08 US disclosed
US-5196419-A Lipoxygenase enzyme inhibitor IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-03-23 US disclosed
US-5134148-A Heterocycles for use as inhibitors of leukotrienes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-07-28 US disclosed
EP-0385679-A2 Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP disclosed
EP-0385663-A2 Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP disclosed
EP-0385662-A2 Heterocycles with inhibitory activity of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331298-A1 Carboxamide Compounds and Their Use CCR2, CCR1, CCR5 BRPF1 2485/4885BRD4 229/4885BRD9 618/4885
US-20100324035-A1 Carboxamide Compounds and Their Use CCR2, CCR1, CCR5 BRPF1 2580/4885BRD4 370/4885BRD9 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.